Detalhe da pesquisa
1.
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
J Med Chem
; 59(7): 3392-408, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27003761
2.
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
ChemMedChem
; 10(2): 276-95, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25430902
3.
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.
Phys Med
; 30(6): 702-7, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685182
4.
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
J Med Chem
; 62(17): 8364, 2019 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424209
5.
Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
ChemMedChem
; 2(4): 528-40, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17335099